NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Greenhalgh J, Bagust A, Boland A, et al. Clopidogrel and Modified-Release Dipyridamole for the Prevention of Occlusive Vascular Events (Review of Technology Appraisal No. 90): A Systematic Review and Economic Analysis. Southampton (UK): NIHR Journals Library; 2011 Sep. (Health Technology Assessment, No. 15.31.)

Cover of Clopidogrel and Modified-Release Dipyridamole for the Prevention of Occlusive Vascular Events (Review of Technology Appraisal No. 90): A Systematic Review and Economic Analysis

Clopidogrel and Modified-Release Dipyridamole for the Prevention of Occlusive Vascular Events (Review of Technology Appraisal No. 90): A Systematic Review and Economic Analysis.

Show details

2Definition of the decision problem

Decision problem

The remit of this appraisal is to review and update (if necessary) the clinical effectiveness and cost-effectiveness evidence base described in TA90.24 Table 4 shows the key elements of the decision problem of the appraisal.

TABLE 4. Key elements of the decision problem.

TABLE 4

Key elements of the decision problem.

The key elements of this appraisal are similar to those that underpin the previous review,3 with the following exceptions: patients with a history of TIA will not be considered in the assessment of the effectiveness of clopidogrel, as clopidogrel is not licensed for this patient group; MI will be divided into STEMI and NSTEMI; and unstable angina has replaced ‘other vascular events’.

Overall aims and objectives of assessment

The purpose of the review is to assess the clinical effectiveness and cost-effectiveness evidence describing the use of clopidogrel and MRD (plus ASA or alone) in the prevention of occlusive vascular events in patients with history of MI, ischaemic stroke or TIA, or established peripheral arterial disease. Evidence relevant to the effectiveness of clopidogrel in patients with multivascular disease will also be considered. This review is an update and focuses on relevant clinical effectiveness and cost-effectiveness evidence that has become available since publication of TA90.24

© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

Bookshelf ID: NBK99912

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.7M)
  • Disable Glossary Links

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...